How Long Does NMPA Drug Registration Take for Foreign Biotech Companies in China?

A detailed timeline breakdown for foreign biotech companies navigating China’s drug registration process under the NMPA in 2025–2026.

Introduction

For foreign biotech companies planning to enter the Chinese pharmaceutical market, understanding the NMPA (National Medical Products Administration) drug registration timeline is critical for business planning, resource allocation, and investor expectations. The drug approval process in China has undergone significant reforms since 2017, with the NMPA implementing measures to accelerate review times while maintaining rigorous safety and efficacy standards. This article provides a comprehensive breakdown of how long NMPA drug registration actually takes for foreign biotech companies, based on current regulations, industry data, and real-world timelines observed in 2025–2026.

The Regulatory Framework: Understanding NMPA Drug Registration

NMPA drug registration is the process by which pharmaceutical products obtain marketing authorization in China. For foreign biotech companies, this process is governed by several key regulations including the Drug Administration Law (revised 2019), the Measures for Drug Registration (2020), and various NMPA guidelines on chemical drugs, biologics, and traditional Chinese medicines. The Center for Drug Evaluation (CDE), an NMPA affiliate, handles the technical review of applications. The total timeline from initial application submission to final NMPA approval typically ranges from 12 to 36 months, depending on the drug category, clinical trial requirements, and whether priority review pathways apply.

Phase 1: Pre-Submission Activities (3–6 Months)

Before formally submitting a drug registration application, foreign companies must complete several preparatory steps. This includes compiling the Common Technical Document (CTD) dossier in Chinese, engaging a qualified China-based agent or legal representative, and conducting pre-submission consultation meetings with the CDE. The pre-submission consultation meeting, while optional for standard applications, is highly recommended for foreign companies unfamiliar with NMPA requirements. During this phase, companies also need to ensure their manufacturing facilities comply with China’s Good Manufacturing Practice (GMP) standards. The pre-submission phase typically takes 3 to 6 months for companies that have already assembled their global CTD dossier and need to adapt it for Chinese submission requirements.

Phase 2: Application Acceptance and Formality Review (1–2 Months)

Once the application dossier is submitted through the NMPA’s online platform, the agency conducts a formality review to check that all required documents are present and properly formatted. This phase typically takes 1 to 2 months. During this period, the NMPA may issue a “Notice of Supplemental Information” (or “Bu Zheng Tong Zhi”) requesting additional documents or clarifications. Foreign companies should ensure they have all certificates notarized, legalized, and translated into Chinese by certified translators to avoid delays at this stage. Common formality review delays include incomplete GMP certificates, missing power of attorney documents, or improperly translated clinical study reports.

Phase 3: Technical Review by CDE (6–18 Months)

The technical review is the longest and most rigorous phase of NMPA drug registration. The CDE convenes review teams comprising clinical pharmacologists, toxicologists, statisticians, and medical experts to evaluate the drug’s safety, efficacy, and quality. For foreign biotech companies, this phase typically lasts 6 to 12 months for chemical drugs and 12 to 18 months for biologics. The CDE operates under a statutory review timeline of 120 working days for chemical drugs and 200 working days for biologics under the 2020 Measures for Drug Registration, but this clock stops whenever the CDE requests additional information. The “clock stop” mechanism is a critical factor — each round of questions from the CDE adds 2 to 4 months to the timeline as the applicant prepares responses and the CDE re-reviews them.

Factors That Extend CDE Review Time

• Complexity of the drug: New molecular entities (NMEs) and first-in-class biologics face longer review times than generics or biosimilars.
• Deficiencies in the dossier: Incomplete or unclear data can trigger multiple rounds of information requests.
• Bridge study requirements: If the CDE requires additional China-specific clinical data, this adds 12 to 24 months for the study itself plus review time.
• GMP compliance issues: Foreign manufacturing facilities may need on-site inspection, which can take 3 to 6 months to schedule and complete.
• Labeling and packaging review: Chinese-language labeling requirements must meet specific NMPA formatting standards.

Phase 4: On-Site Inspection and Sample Testing (2–4 Months)

After the technical review, the NMPA may conduct on-site inspections of manufacturing facilities and require sample testing at Chinese drug testing laboratories. For foreign biotech companies, the inspection is typically conducted by the NMPA’s Center for Food and Drug Inspection (CFDI). Remote inspection options, which became more common after the COVID-19 pandemic, have helped reduce this phase to approximately 2 to 3 months. However, for complex biologics or sterile manufacturing facilities, on-site physical inspections may still be required, extending this phase to 3 to 4 months. Sample testing at NIFDC (National Institutes for Food and Drug Control) usually adds an additional 30 to 60 working days for standard drugs and up to 90 working days for biologics.

Phase 5: Final Approval and Certificate Issuance (1–2 Months)

Following successful completion of the technical review, inspections, and sample testing, the NMPA issues the Drug Registration Certificate (also known as the “Marketing Authorization”). The final administrative approval and certificate issuance typically takes 1 to 2 months. Once approved, the drug is assigned a unique approval number (Guo Yao Zhun Zi) and listed on the NMPA’s approved drug database. The certificate is valid for 5 years and must be renewed before expiry. For foreign companies, the approval certificate is issued in the name of the China-based agent or legal representative specified in the application.

Priority Review and Accelerated Pathways

Foreign biotech companies can leverage several accelerated pathways to shorten the NMPA drug registration timeline:

• Priority Review: For drugs that address serious or life-threatening conditions with no effective treatment options in China, NMPA priority review can reduce the total timeline to 6 to 12 months (for chemical drugs) or 12 to 18 months (for biologics). This pathway has been used for innovative cancer therapies, rare disease drugs, and pediatric medicines.
• Breakthrough Therapy Designation: For drugs that demonstrate substantial improvement over existing therapies, CDE’s breakthrough therapy designation provides intensive guidance and faster review.
• Conditional Approval: For drugs addressing urgent public health needs, conditional approval allows market access based on surrogate endpoints, with post-marketing studies required to confirm clinical benefit.
• Mutual Recognition / ICH Alignment: China is now fully aligned with ICH (International Council for Harmonisation) guidelines, meaning foreign clinical trial data can be accepted for NMPA applications, potentially eliminating the need for separate China-based bridging studies.

Real-World Timelines: What Foreign Companies Report

Based on industry reports and publicly available NMPA approval data for 2023–2025, the following real-world timelines have been observed for foreign biotech companies:

• Chemical generics (Class 3 and 4): 12–18 months total
• Innovative chemical drugs (Class 1): 18–24 months total (6–12 months with priority review)
• Therapeutic biologics (Class 1): 24–36 months total (12–18 months with priority review)
• Biosimilars: 18–30 months total
• Vaccines: 12–24 months (depending on public health urgency)

It is important to note that these timelines assume the foreign company has already completed or initiated required clinical trials in China. If China-specific clinical trials are needed from scratch, an additional 12 to 36 months must be budgeted, making the total timeline 3 to 6 years depending on the drug category.

Common Delays and How to Avoid Them

Foreign biotech companies frequently encounter the following delays during NMPA drug registration:

• Incomplete dossier translation: All CTD documents must be professionally translated into Chinese and certified. Poor translation can lead to misunderstandings and additional review rounds.
• Missing ethnic sensitivity data: The CDE requires data on how ethnic factors may affect the drug’s pharmacokinetics and pharmacodynamics in Chinese populations.
• Manufacturing site changes: Any change to the manufacturing site during the review process requires re-submission and restarts the clock.
• Unfamiliarity with Chinese regulatory expectations: Hiring an experienced China regulatory affairs consultant or partnering with a local CRO can significantly reduce delays.

Strategic Recommendations for Foreign Biotech Companies

To minimize the NMPA drug registration timeline, foreign biotech companies should consider the following strategies:

1. Start early: Begin the China registration process in parallel with US FDA or EMA submissions rather than sequentially. Many companies make the mistake of completing global registration before starting the China process, wasting 12–24 months.
2. Engage CDE pre-submission meetings: Request a pre-submission consultation meeting 6–12 months before submission to align expectations and identify potential issues early.
3. Participate in ICH E5/E17 bridging study guidance: Design China-bridging studies that satisfy both CDE requirements and global development plans.
4. Consider the Greater Bay Area or Hainan Bo’ao pilot programs: Some special zones in China offer expedited drug approval pathways for imported drugs used in designated medical institutions.
5. Build a China regulatory team: Either in-house or through a qualified regulatory affairs consulting firm with proven NMPA submission experience.

Conclusion

For foreign biotech companies, NMPA drug registration typically takes 12 to 36 months for standard applications, with priority review pathways reducing this to 6 to 18 months. The total timeline depends heavily on the drug category, the completeness of the submission dossier, whether China-specific clinical trials are required, and the company’s preparedness for CDE information requests. By understanding the detailed phases of the approval process — pre-submission, formality review, technical review, inspection and testing, and final approval — foreign companies can better plan their China market entry strategy and avoid common pitfalls. With China’s continued alignment with international regulatory standards under ICH and the NMPA’s ongoing efforts to accelerate drug approvals, the registration process is becoming more predictable and efficient for foreign biotech companies in 2025 and beyond.

This article is for informational purposes only and does not constitute legal or regulatory advice. Timelines mentioned are estimates based on current regulations and industry data as of 2025–2026. Foreign companies should consult qualified regulatory affairs professionals for advice specific to their drug product and circumstances.